Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2765-2775

This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hockin, M. F.
Right arrow Articles by Mann, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hockin, M. F.
Right arrow Articles by Mann, K. G.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2765-2775.)
© 1997 American Heart Association, Inc.


Articles

Protein C Activation and Factor Va Inactivation on Human Umbilical Vein Endothelial Cells

Matthew F. Hockin; Michael Kalafatis; Marie Shatos; ; Kenneth G. Mann

From the College of Medicine, Department of Biochemistry, University of Vermont, Burlington.

Correspondence to Kenneth G. Mann, College of Medicine, Department of Biochemistry, University of Vermont, Burlington, VT 05405-0068. E-mail kmann{at}protein.med.uvm.edu

Abstract The inactivation of factor Va was examined on primary cultures of human umbilical vein endothelial cells (HUVECs), either after addition of activated protein C (APC) or after addition of {alpha}-thrombin and protein C (PC) zymogen. Factor Va proteolysis was visualized by Western blot analysis using a monoclonal antibody ({alpha}HVaHC No. 17) to the factor Va heavy chain (HC), and cofactor activity was followed both in a clotting assay using factor V–deficient plasma and by quantitation of prothrombinase function. APC generation was monitored using the substrate 6-(D-VPR)amino-1-naphthalenebutylsulfonamide (D-VPR-ANSNHC4H9), which permits quantitation of APC at 10 pmol/L. Addition of APC (5 nmol/L) to an adherent HUVEC monolayer (3.5x105 cells per well) resulted in a 75% inactivation of factor Va (20 nmol/L) within 10 minutes, with complete loss of cofactor activity within 2 hours. Measurements of the rate of cleavage at Arg506 and Arg306 in the presence and absence of the HUVEC monolayer indicated that the APC-dependent cleavage of the factor Va HC at Arg506 was accelerated in the presence of HUVECs, while cleavage at Arg306 was dependent on the presence of the HUVEC surface. Factor Va inactivation proceeded with initial cleavage of the factor Va HC at Arg506, generating an Mr 75 000 species. Further proteolysis at Arg306 generated an Mr 30 000 product. When protein C (0.5 µmol/L), {alpha}-thrombin (1 nmol/L), and factor Va (20 nmol/L) were added to HUVECs an APC generation rate of 1.56±0.11x10-14 mol/min per cell was observed. With APC generated in situ, cleavage at Arg506 on the HUVEC surface is followed by cleavage at Arg306, generating Mr 75 000 and Mr 30 000 fragments, respectively. In addition, the appearance of two novel products derived from the factor Va HC are observed when thrombin is present on the HUVEC surface: the HC is processed through limited thrombin proteolysis to generate an Mr 97 000 fragment, which is further processed by APC to generate an Mr 43 000 fragment. NH2-terminal sequence analysis of the Mr 97 000 fragment revealed that the thrombin cleavage occurs in the COOH-terminus of the intact factor Va HC since both the intact HC as well as the Mr 97 000 fragment have the same sequence. Our data demonstrate that the inactivation of factor Va on the HUVEC surface, initiated either by APC addition or PC activation, follows a mechanism whereby cleavage is observed first at Arg506 followed by a second cleavage at Arg306. The latter cleavage is dependent on the availability of the HUVEC surface. This mechanism of inactivation of factor Va is similar to that observed on synthetic phospholipid vesicles.


Key Words: factor Va • protein C • endothelial cells • thrombomodulin




This article has been cited by other articles:


Home page
BloodHome page
A. Undas, K. Szuldrzynski, K. E. Brummel-Ziedins, W. Tracz, K. Zmudka, and K. G. Mann
Systemic blood coagulation activation in acute coronary syndromes
Blood, February 26, 2009; 113(9): 2070 - 2078.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Undas, K. E. Brummel-Ziedins, and K. G. Mann
Statins and Blood Coagulation
Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 287 - 294.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. van der Neut Kolfschoten, R. J. Dirven, H. L. Vos, G. Tans, J. Rosing, and R. M. Bertina
Factor Va Is Inactivated by Activated Protein C in the Absence of Cleavage Sites at Arg-306, Arg-506, and Arg-679
J. Biol. Chem., February 20, 2004; 279(8): 6567 - 6575.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. R. Gould, J. R. Silveira, and P. B. Tracy
Unique in Vivo Modifications of Coagulation Factor V Produce a Physically and Functionally Distinct Platelet-derived Cofactor: CHARACTERIZATION OF PURIFIED PLATELET-DERIVED FACTOR V/Va
J. Biol. Chem., January 23, 2004; 279(4): 2383 - 2393.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. G. Mann and M. Kalafatis
Factor V: a combination of Dr Jekyll and Mr Hyde
Blood, January 1, 2003; 101(1): 20 - 30.
[Full Text] [PDF]


Home page
BloodHome page
J. A. Oliver, D. M. Monroe, F. C. Church, H. R. Roberts, and M. Hoffman
Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces
Blood, June 28, 2002; 100(2): 539 - 546.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Undas, K. Brummel, J. Musial, K. G. Mann, and A. Szczeklik
Blood coagulation at the site of microvascular injury: effects of low-dose aspirin
Blood, October 15, 2001; 98(8): 2423 - 2431.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Undas, K. E. Brummel, J. Musial, K. G. Mann, and A. Szczeklik
Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation
Circulation, May 8, 2001; 103(18): 2248 - 2253.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Castoldi, P. Simioni, M. Kalafatis, B. Lunghi, D. Tormene, D. Girelli, A. Girolami, and F. Bernardi
Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family
Blood, August 15, 2000; 96(4): 1443 - 1448.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Kalafatis and K. G. Mann
The Role of the Membrane in the Inactivation of Factor Va by Plasmin. AMINO ACID REGION 307-348 OF FACTOR V PLAYS A CRITICAL ROLE IN FACTOR Va COFACTOR FUNCTION
J. Biol. Chem., May 18, 2001; 276(21): 18614 - 18623.
[Abstract] [Full Text] [PDF]